Forte Biosciences (FBRX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases.

• Lead product candidate FB102 is an anti-CD122 monoclonal antibody targeting key immune pathways.

• FB102 has shown promising in-vitro and in-vivo results, including significant inhibition of T and NK cell proliferation and activation.

• Ongoing clinical programs include Phase 1b and Phase 2 trials in celiac disease, vitiligo, and alopecia areata.

• FB102 may have broader applications in diseases such as type 1 diabetes.

Financial performance and metrics

• No dividends have been paid and there are no current plans to pay dividends.

• The company qualifies as a smaller reporting company, allowing for reduced disclosure requirements.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used at management's discretion, with specific uses detailed in future prospectus supplements.